How effective is selinesol in treating multiple myeloma?

Selinexor is a new targeted drug that has attracted much attention in the field of tumor treatment in recent years, especially showing important potential in the treatment of multiple myeloma (MM). As the first SINE nuclear export inhibitor approved by the FDA, its mechanism of action is different from traditional chemotherapy or simple immunomodulators. It can retain tumor suppressor proteins such as p53 in tumor cells and induce cell apoptosis. It has a special effect on certain drug-resistant myeloma cells.

In the treatment of patients with advanced or relapsed and refractory multiple myeloma, especially those who have failed multiple lines of therapy and have become resistant to proteasome inhibitors, immunomodulators and monoclonal antibodies, the treatment regimen consisting of selinesol combined with dexamethasone has become an optional therapy. It is suitable for high-risk groups with complex clinical backgrounds that are ineffective in standard regimens, filling the gaps in existing treatments.

According to overseas research results, some patients can achieve disease remission, M protein reduction, and myeloma cell reduction after combined treatment with selinesol. Although the efficacy of this drug is more individualized, it can still bring survival benefits in some refractory lesions. It should be pointed out that the efficacy of selinesol usually does not exist in isolation, but in combination with other drugs, its sensitizing effect can be better reflected.

For example, more common clinical combination regimens include combinations with drugs such as bortezomib (Bortezomib), dexamethasone, and lenalidomide, and the regimen can be adjusted according to the patient's condition. At the same time, we need to be alert to its adverse reactions, such as nausea, fatigue, decreased appetite, hyponatremia, and thrombocytopenia. Patients with physical weakness or liver and kidney dysfunction need special monitoring. In terms of managing the balance between efficacy and toxicity, it is recommended that hematologists with extensive experience prescribe and regularly evaluate treatment response and tolerance.

In summary, selinesol provides new hope in the treatment of multiple myeloma, especially as a complementary therapy for relapsed and refractory patients, providing a new way to prolong survival and improve quality of life.

Reference materials:https://www.selincro.com/